Comparison of methotrexate and methylprednisolone as addition to antifibrotic therapy in progressive pulmonary fibrosis due to COVID-19.
Methotrexate can be used as an alternative to methylprednisolone in PCPF due to its low side effect profile and its effectiveness in PFT, 6MWT, and saturation levels.
Authors
- Buğra Kerget (ORCID: https://orcid.org/0000-0002-6048-1462)
- Fatih Alper
- Leyla Sağlam (ORCID: https://orcid.org/0000-0002-7040-3433)
- İsmail Çınar
- Burcu Nur Gülbahar
Institutions
- Atatürk University (TR)
Publication Details
- Journal
- PubMed
- Published
- 2024-12-10
- DOI
- https://doi.org/10.36141/svdld.v41i4.15614
- Citations
- 1
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.42